TOP TEN perturbations for P18146 (Homo sapiens)

Organism: Homo sapiens
Gene: P18146
Selected probe(set): 201694_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P18146 (201694_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):7.6375475
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 ?g/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

Burkitt lymfoma study 4 (MAP2K inhibitor) / Burkitt lymfoma study 4 (control)

Relative Expression (log2-ratio):-6.276594
Number of Samples:3 / 5
Experimental Burkitt lymfoma study 4 (MAP2K inhibitor)
BL-2 cell line with activated B cell receptor (BCR) through ?IgM treatment and isolated after MAP2K inhibition. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.
Control Burkitt lymfoma study 4 (control)
BL-2 cell line with activated B cell receptor (BCR) through ?IgM treatment. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.

ELK1 depletion study 1 (siRNA; EGF) / ELK1 depletion study 1 (siRNA)

Relative Expression (log2-ratio):5.5598307
Number of Samples:3 / 3
Experimental ELK1 depletion study 1 (siRNA; EGF)
MCF10A cell line transfected with 20 nM targeting ELK1 for 48 hours. Cells were then stimulated with complete media containing 20 ng/ml EGF for 30 minutes. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. ATC code:---
Control ELK1 depletion study 1 (siRNA)
MCF10A cell line transfected with 20 nM targeting ELK1 for 48 hours. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours.

sapphyrin PCI-5002; ZnOAc2 study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):5.383091
Number of Samples:3 / 3
Experimental sapphyrin PCI-5002; ZnOAc2 study 1
A549 human lung cancer cells were seeded 8 days. At 4 hours prior to RNA isolation, PCI-5002 (10 ?M final concentration) + ZnOAc2 (25 ?M final concentration) solution was added to the cultures. ATC code:---
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded 8 days. At 4 hours prior to RNA isolation, 5% mannitol solution was added to the cultures.

ELK1 depletion study 1 (siRNA; EGF) / control siRNA transfected MCF10A cell sample

Relative Expression (log2-ratio):5.2322216
Number of Samples:3 / 3
Experimental ELK1 depletion study 1 (siRNA; EGF)
MCF10A cell line transfected with 20 nM targeting ELK1 for 48 hours. Cells were then stimulated with complete media containing 20 ng/ml EGF for 30 minutes. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. ATC code:---
Control control siRNA transfected MCF10A cell sample
MCF10A cell line transfected with 20 nM control siRNA (siGAPDH) for 48 hours. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours.

bladder cancer study 1 / normal bladder tissue

Relative Expression (log2-ratio):-5.2209845
Number of Samples:3 / 3
Experimental bladder cancer study 1
Low grade superficial tumor samples.
Control normal bladder tissue
Normal bladder tissue.

control siRNA transfected MCF10A cell sample (EGF) / control siRNA transfected MCF10A cell sample

Relative Expression (log2-ratio):4.926882
Number of Samples:3 / 3
Experimental control siRNA transfected MCF10A cell sample (EGF)
MCF10A cell line transfected with 20 nM control siRNA (siGAPDH) for 48 hours. Cells were then stimulated with complete media containing 20 ng/ml EGF for 30 minutes. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours.
Control control siRNA transfected MCF10A cell sample
MCF10A cell line transfected with 20 nM control siRNA (siGAPDH) for 48 hours. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-4.9232063
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

tumor supernatant activation study 3 / untreated memory CD4 T-cell sample

Relative Expression (log2-ratio):4.852051
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control untreated memory CD4 T-cell sample
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):-4.801874
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.